RSNA 2017
Welcome to our Media Breakfast

Walter Maerzendorfer
November 2017
Disclaimer

This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens’ management, of which many are beyond Siemens’ control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Risks in the Annual Report. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
Who we are

- > 70% of critical clinical decisions are influenced by the type of technology we provide
- > 11,000 granted patents globally
- 47,000 employees
- Access for 1.27 bn people in emerging countries
- €13.8 bn revenue
- 75 countries with direct presence
- World market leader in most businesses
- Biggest of medtech infrastructure
- > €1 bn R&D spent
- > 209,000 patients every hour

2) Siemens AG, "Sustainability Information 2016", page 8
3) Siemens AG, "Sustainable healthcare strategy – Indicators in fiscal 2014", page 3–4
Global dynamics in healthcare

Healthcare trends
- Consumerism
- Demographic shift
- Population growth
- Rapid scientific progress
- Staff shortage
- Shift to value-based reimbursement
- Growing chronic disease burden
- Increasing cost pressure

Transformation of healthcare providers
- Consolidation
  - Building the critical mass
- Industrialization
  - Doing more with less
- Managing Health
  - Value-based healthcare
Our purpose is to make healthcare providers succeed

Enabling better outcomes at lower costs
We enable healthcare providers to achieve better outcomes at lower costs by empowering them on their journey towards...

- Expanding precision medicine
- Transforming care delivery
- Improving patient experience
- Digitalizing healthcare
1) The FAST 3D Camera is pending 510(k) clearance, and is not yet commercially available in the United States.
2) This product is pending 510(k) clearance, and is not yet commercially available in the United States.
3) Biograph Vision and its features and applications are currently under development and are not for sale in the U.S. Their future availability cannot be guaranteed. They do not yet fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations and are not yet commercially available in the European Union.
4) Cios Spin is currently under development; is not for sale in the U.S. Its future availability cannot be guaranteed.
A strong MR portfolio
Innovating Magnetic Resonance

1) MR scanning has not been established as safe for imaging fetuses and infants less than two years of age. The responsible physician must evaluate the benefits of the MR examination compared to those of other imaging procedures.
A strong MI portfolio
Innovating Molecular Imaging

1) Biograph Vision and its features and applications are currently under development and are not for sale in the U.S. Their future availability cannot be guaranteed. They do not yet fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations and are not yet commercially available in the European Union.

2) These products are not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
A strong XP portfolio
Innovating general X-ray

Twin Robotic X-ray
Multitom Rax

Radiography
Ysio Max,
Multix Fusion Max,
Multix Select DR

Mobile X-ray
Mobilett Mira Max,
Mobilett XP Series,
Polymobil Plus,
Multimobil 10

Fluoroscopy
Luminos Agile Max,
Luminos dRF Max,
Luminos Select,
Luminos RF Classic

Unrestricted © Siemens Healthcare GmbH, 2017
A strong portfolio
Innovating Urology & Women’s Health

1) This product is pending 510(k) clearance, and is not yet commercially available in the United States.
A strong US portfolio
Innovating Ultrasound

**General Imaging**
- **ACUSON**
  - S3000, S2000, S1000
- **ACUSON**
  - X700, X600
- **ACUSON**
  - NX3 Elite, NX3, NX2 Elite, NX2

**Cardiology**
- **ACUSON**
  - SC2000
- **ACUSON**
  - P500 ICE Edition

**Women’s Health**
- **ACUSON**
  - S2000 ABVS

**syngo Ultrasound Breast Analysis (sUSBA)**

**Portable**
- **ACUSON**
  - Freestyle, Freestyle Elite
- **ACUSON**
  - P500

**Advanced Applications**
- Cadence Contrast Imaging
- Virtual Touch
- eSieFusion Imaging

**Customer Technologies**
- Healthcare IT

**Fusion Technologies**
- eSieFusion Imaging

**Elastography Technologies**
- AcuNav V Catheter

**Contrast Enhanced Ultrasound (CEUS) Technologies**
A strong CT portfolio
Innovating Computer Tomography

1) This product is pending 510(k) clearance, and is not yet commercially available in the United States.
2) For research use only. Not for clinical use.
3) The FAST 3D Camera is pending 510(k) clearance, and is not yet commercially available in the United States.
Patient-centric technologies of SOMATOM go.platform now available for the full clinical spectrum

1) This product is pending 510(k) clearance, and is not yet commercially available in the United States.
Patient positioning is significantly influencing dose and image quality.

In 95% of all patients, isocentering is incorrect. About 2.6 cm mean deviation.

3 cm

+ 18% peripheral dose

+ 6% noise

Introducing the first
FAST Integrated Workflow
with FAST 3D Camera

✓ Standardized positioning
✓ Isocentric positioning
✓ Correct body region recognition
✓ Correct scan direction setup

1) The FAST 3D Camera is pending 510(k) clearance, and is not yet commercially available in the United States.
FAST Integrated Workflow and FAST 3D Camera\(^1\) introduced to our premium systems, both Single and Dual Source

1) The FAST 3D Camera is pending 510(k) clearance, and is not yet commercially available in the United States.
2) This product is pending 510(k) clearance, and is not yet commercially available in the United States.
Contrast media enhanced 100 kV imaging at BMI 51 for whole-body evaluation with SOMATOM Edge Plus\textsuperscript{1)}

\textsuperscript{1)} This product is pending 510(k) clearance, and is not yet commercially available in the United States.
The new CT portfolio is a strong player for our Siemens Healthineers value promises

Expanding precision medicine  
Transforming care delivery  
Improving patient experience  
Digitalizing healthcare

...enabled by digital technologies
The new CT portfolio is a strong player for our Siemens Healthineers value promises

Expanding precision medicine
- Precise diagnosis to foster individualized prevention & therapy

Transforming care delivery
- Accessible & highly-efficient health care delivery leveraging established & new care models

Improving patient experience
- Improved patient experience across the continuum of care

Digitalizing healthcare
...enabled by digital technologies
Seamlessly combined multi-modality imaging to advance therapy outcomes

nexaris Angio-MR-CT
At the nexus of treatment innovation

Safer, faster, more precise and less costly procedures
nexaris Therapy Suites
Multi-modality imaging to advance therapy outcomes

nexaris Angio-CT – for interventional radiology
enabled by Instant Fusion

nexaris Angio-MR-CT – for surgery
enabled by PILOT
Interventional oncology procedure in a 75 year old male with liver cancer

Intra-arterial CTA

Embolization

3D-guided ablation

Combined ablation and embolization in one session

Courtesy: Dr. B. Odisio, MD Anderson Cancer Center, Houston, US.
A strong AT portfolio
Innovating Advanced Therapy

1) This product is pending 510(k) clearance, and is not commercially available in the United States
2) Cios Spin is currently under development; is not for sale in the U.S. Its future availability cannot be guaranteed.
Expanding the core:
Siemens Healthineers coherent portfolio gains recognition
Disruptive developments enable data-driven precision medicine

Technological trends

- Artificial Intelligence
- Big data
- 3D-Printing
- Augmented reality
- Robotics

Data-driven precision medicine

Healthcare trends

- Value based healthcare
- Information transparency
- Data explosion
- “Population Health Management” & prevention
Beyond the core: Digitalization today and tomorrow

**syngo.via**
routine reading and reporting

**syngo.via**
OpenApps

**Syngo Healthineers Digital Ecosystem**

1) **syngo.via** can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via and the syngo.via-based software options are not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

2) Siemens Healthineers Digital Ecosystem is not commercially available in all countries. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
Digitalizing Healthcare enabled by digital technologies

Improving patient experience

AI drives outcomes that matter to patients by
• prioritizing complex/acute cases
• avoiding unnecessary interventions

AI drives efficiency and productivity by enabling
• increased workforce productivity through assistance in automation
• clinical operations optimization

Transforming care delivery

Expanding precision medicine

AI drives quality of care by increasing
• diagnostic precision through quantitative imaging
• personalization with intelligent image acquisition
Powerful platform combined with long-term experience for Artificial Intelligence

- 600,000 imaging, laboratory and point-of-care systems
- Touching 200,000 patients every hour
- 100,000,000 curated images, reports, operational data
- Close clinical collaborations
- Dedicated annotation team
- AI competence center with awarded Data Scientists
- Regional supercomputing data centers
- More than 30 AI-powered offerings on the market
- 400 patents and patent applications in machine learning
- 75 in deep learning

Unrestricted © Siemens Healthcare GmbH, 2017
Siemens Healthineers Digital Ecosystem
Open and secured environment for digitalizing healthcare

Siemens Healthineers Digital Ecosystem is not commercially available in all countries. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
We’re looking forward to another great RSNA in 2017

Outstanding product portfolio

Remarkable innovation pipeline

Extensive customer network

... and highly experienced global teams